A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations
Phase of Trial: Phase III
Latest Information Update: 28 Dec 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Registrational; Therapeutic Use
- Acronyms ReTHINK
- Sponsors Novartis Pharmaceuticals Corporation
- 30 Nov 2017 This trial has been completed in Greece (end date: 23 Oct 2017).
- 09 Nov 2017 This trial has been completed in Belgium (end date: 23 Oct 2017).
- 19 Jul 2017 This trial was completed in Austria, according to European Clinical Trials Database record.